Emeritus Research Icon Circle Icon Left Arrow Right Arrow Up Arrow Facebook Icon Instagram Icon LinkedIn Icon Process Circle Right Process Circle Left Process Circle Process Circle Bottom

Therapeutic Area

Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)

Eligibility Criteria

  • Male or female adults 18+ years old
  • Have taken Methotrexate for 3+ months and been on a stable dose for at least 1 month
  • Meet joint count eligibility criteria
  • Subject has at least one of the following at Screening: a. ≥ 3 bone erosions on x-ray; or b. ≥ 1 bone erosion and a positive rheumatoid factor (RF); or c. ≥ 1 bone erosion and a positive anti-cyclic citrullinated peptide (anti-CCP) autoantibody
  • Stable dose of NSAIDs
  • No prior exposure to any JAK inhibitor or exposure to more than one biologic medications

Trial Details

5 years
Year 1: Visits at Week 2, 4, 8, 12, 14, 18, 22, 26, 30, 36, 42, 48
Year 2-5: Quarterly visits

Status

In progress

Therapeutic Area

Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)

Eligibility Criteria

  • Male or female adults 18+ years old
  • Subjects have been treated with bDMARD therapy for RA in the past and failed at least 1 bDMARD therapy prior to first dose of study drug
  • Subjects have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug
  • Stable dose of NSAIDs, paracetamol and corticosteroids
  • Meet joint count eligibility criteria No prior exposure to any JAK inhibitor

Trial Details

4.5 years
Monthly visits until week 24 then quarterly visits

Status

In progress

Therapeutic Area

Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

Eligibility Criteria

  • Male or female adults 18+ years old
  • Subjects have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug
  • Stable dose of NSAIDs, paracetamol and corticosteroids
  • Meet joint count eligibility criteria No prior exposure to any JAK inhibitor or exposure to more than one biologic medications

Trial Details

5 years and
Monthly visits until week 24 then quarterly visits

Status

In progress

Therapeutic Area

Early Rheumatoid Arthritis who are Methotrexate Naive

Eligibility Criteria

  • Early RA diagnosis
  • Joint count and inflammatory marker eligibility
  • No previous exposure to any treatment with an approved or investigational conventional (non-biologic) or biologic DMARD

Trial Details

2 years
Visits: week 4, 8, 12, 16, 24, 28, 40, 52, 56, 60, 64, 72, 80, 88, 96, 104
Follow-up visits x 3

Status

In progress

Therapeutic Area

Active Idiopathic Inflammatory Myopathy

Eligibility Criteria

  • Male or female adults 18+ years old
  • Demonstrable muscle weakness measured by the MMT-8

Trial Details

1 year study

Status

In progress

Therapeutic Area

Ankylosing Spondylitis

Eligibility Criteria

  • Male or female adults 18+ years old
  • Radiographic criteria documented by the central reader
  • Clinical criteria documented in physical examination

Trial Details

5 years
Visits at weeks 4, 12, 16, 24, then quarterly

Status

In progress

Therapeutic Area

Psoriatic Arthritis

Eligibility Criteria

  • Male or female adults 18+ years old
  • Willing and able to undergo MRI scans
  • Stable dose of PsA treatment

Trial Details

1 year
Quarterly visits

Status

In progress

Therapeutic Area

Rheumatoid Arthritis

Eligibility Criteria

  • Male or female adults 18+ years old
  • Completion of a qualifying parent study

Trial Details

4 year extension study with quarterly visits

Status

In progress

Therapeutic Area

Psoriatic Arthritis

Eligibility Criteria

  • Male or female adults 18+ years old
  • Have been treated with 1+ cDMARDs
  • Have had prior treatment with at least 1 and not more than 2 TNF inhibitors

Trial Details

3 years
Year 1: weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 44, 52
Year 2-3:
Quarterly visits

Status

In progress

Therapeutic Area

Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive

Eligibility Criteria

  • Male or female adults 18+ years old
  • Cannot have used csDMARDs other than MTX, leflunomide, sulfasalazine, or cyclosporine or hydroxychloroquine in the 8 weeks prior to randomization
  • Have received any prior, or are currently receiving, treatment with any bDMARD therapy or small-molecule for PsA or for psoriasis

Trial Details

1 year

Status

Coming soon

Therapeutic Area

Type 2 Diabetes

Eligibility Criteria

  • Male or female adults 18-70yo
  • Body Mass Index (BMI) ≥27 kg/m2 and <40 kg/m2
  • Must meet laboratory criteria for HbA1C, C-peptide and lipids
  • Able to maintain a paper diary

Trial Details

Up to 21 weeks

Status

Coming soon

Therapeutic Area

Chronic Obstructive Pulmonary Disease

Eligibility Criteria

  • Males and females 40+ years
  • Outpatient with a diagnosis of COPD
  • FEV1 and CAT score criteria
  • Completion of an electronic diary

Trial Details

Six months

Status

Coming soon

Therapeutic Area

Systemic Lupus Erythematosus

Eligibility Criteria

  • Males and females 18-75 years of age
  • Have SLE by meeting the SLICC classification criteria
  • ANA, and/or anti-dsDNA antibodies, and/or anti-Smith antibodies eligibility criteria
  • BILAG and SLEDAI-2K eligibility criteria

Trial Details

2 years
Monthly visits

Status

In progress

Therapeutic Area

Psoriatic Arthritis

Eligibility Criteria

  • Male or female adults 18+ years old
  • Diagnosis of PsA classified by CASPAR criteria
  • Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies negative at screening
  • Prior or current NSAID use
  • Cannot have used biologics except those targeting TNF (but no more than 3 agents used)

Trial Details

2 years
Year 1: Weekly visits for 4 weeks, then monthly
Year 2: Quarterly visits

Status

In progress

Therapeutic Area

Psoriatic Arthritis

Eligibility Criteria

  • This is an extension study from a 2 year parent study

Trial Details

3 years
Quarterly visits

Status

In progress

Therapeutic Area

Psoriatic Arthritis

Eligibility Criteria

  • Male or female adults 18+ years old
  • Diagnosis of PsA classified by CASPAR criteria
  • Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies negative at screening
  • Prior or current NSAID use

Trial Details

3 years
Year 1: Weekly visits for 4 weeks, then monthly
Year 2: Every 2 months
Year 3:  Quarterly visits

Status

In progress

Therapeutic Area

Psoriatic Arthritis

Eligibility Criteria

  • Male or female adults 18+ years old
  • Diagnosis of PsA classified by CASPAR criteria
  • Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies negative at screening
  • Prior or current NSAID use

Trial Details

5 years
Year 1-2: Weekly visits for 4 weeks, then monthly
Year 3-5: Quarterly visits

Status

In progress

Therapeutic Area

Ankylosing spondylitis

Eligibility Criteria

  • Male or female adults 18+ years old
  • Diagnosis of moderate to severe AS with prior documented radiologic evidence
  • BASDAI eligibility
  • NSAID use with an inadequate response or failure to respond

Trial Details

2 years
Year 1: Weekly visits for 4 weeks, then monthly
Year 2: Quarterly visits

Status

In progress

Therapeutic Area

Rheumatoid arthritis

Eligibility Criteria

  • Male or female adults 18+ years old
  • Have moderate to severe disease activity as defined by CDAI>10and DAS28-4(ESR) ≥3.2at Baseline Visit
  • Joint count eligibility
  • Methotrexate 4+ months with an inadequate response
  • Cannot have had a history of insufficient response to ≥2 biologics, regardless of the class

Trial Details

48 weeks
Visits: weeks 6, 12, 24, 36, 48

Status

Coming soon

Therapeutic Area

Psoriatic arthritis

Eligibility Criteria

  • This is a long-term extension study from a qualifying parent study

Trial Details

3 years
Visits: Quarterly

Status

In progress

Therapeutic Area

Axial spondyloarthritis

Eligibility Criteria

  • Male or female adults 18+ years old
  • Meets ASAS criteria
  • Subjects must NOT have sacroiliitis defined by mNY criteria on SI x-rays
  • BASDAI eligibility criteria
  • MRI+/CRP+ or MRI+/CRP- or MRI-/CRP+
  • Prior use of 2+ NSAIDs

Trial Details

1 Year
Monthly visits

Status

In progress

Therapeutic Area

Knee Pain due to Osteoarthritis

Eligibility Criteria

  • Males and females 40-70yo
  • Knee pain for 12+ months
  • Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification Grade 2, 3, or 4
  • Able and willing to maintain a daily pain and daily skin check diary

Trial Details

12 weeks
Visits: Monthly

Status

In progress

Therapeutic Area

Healthy volunteers for a vaccine

Eligibility Criteria

  • Aged 50+
  • Subjects with an increased risk of future contact with healthcare systems (e.g. had hospitalisation/emergency room visit in the last 12 months), or recent antibiotic use

Trial Details

Endpoint driven

Status

Coming soon